ATE530181T1 - Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel - Google Patents

Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel

Info

Publication number
ATE530181T1
ATE530181T1 AT07724008T AT07724008T ATE530181T1 AT E530181 T1 ATE530181 T1 AT E530181T1 AT 07724008 T AT07724008 T AT 07724008T AT 07724008 T AT07724008 T AT 07724008T AT E530181 T1 ATE530181 T1 AT E530181T1
Authority
AT
Austria
Prior art keywords
prophylaxis
treatment
ynylamin
omigapil
oxepin
Prior art date
Application number
AT07724008T
Other languages
English (en)
Inventor
Thomas Meier
Original Assignee
Santhera Pharmaceuticals Ch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santhera Pharmaceuticals Ch filed Critical Santhera Pharmaceuticals Ch
Application granted granted Critical
Publication of ATE530181T1 publication Critical patent/ATE530181T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
AT07724008T 2006-04-05 2007-04-04 Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel ATE530181T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06007217A EP1842539A1 (de) 2006-04-05 2006-04-05 Verwendung von N-(dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung und/oder Behandlung von angeborener Muskeldystrophie oder Myopathie verursacht durch einen Kollagen IV Mangel
PCT/EP2007/003067 WO2007115776A1 (en) 2006-04-05 2007-04-04 USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY

Publications (1)

Publication Number Publication Date
ATE530181T1 true ATE530181T1 (de) 2011-11-15

Family

ID=36190429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07724008T ATE530181T1 (de) 2006-04-05 2007-04-04 Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel

Country Status (16)

Country Link
US (1) US7875648B2 (de)
EP (2) EP1842539A1 (de)
JP (1) JP4972156B2 (de)
AT (1) ATE530181T1 (de)
AU (1) AU2007236161B2 (de)
CA (1) CA2648155C (de)
CY (1) CY1112132T1 (de)
DK (1) DK2004176T3 (de)
ES (1) ES2371627T3 (de)
MX (1) MX2008012867A (de)
NZ (1) NZ571129A (de)
PL (1) PL2004176T3 (de)
PT (1) PT2004176E (de)
SI (1) SI2004176T1 (de)
WO (1) WO2007115776A1 (de)
ZA (1) ZA200807800B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757284A1 (de) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Verwendung von N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung oder Behandlung der Muskulardystrophy
US9937144B2 (en) 2013-01-30 2018-04-10 The Johns Hopkins University Treatment of drug abuse by preventing GAPDH nitrosylation
US20240269091A1 (en) 2021-06-07 2024-08-15 Katholieke Universiteit Leuven Idebenone in the treatment of drug resistant epilepsy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780244A (en) 1993-09-27 1998-07-14 La Jolla Cancer Research Foundation Changes in laminin subunit composition are diagnostic of Fukuyama congenital muscular dystrophy
US5863743A (en) 1994-08-12 1999-01-26 University Of Iowa Research Foundation Merosin deficiency-type congenital muscular dystrophy
DE59607332D1 (de) 1995-02-08 2001-08-30 Novartis Ag Antineurodegenerativ wirksame 10-Aminoaliphatyl-dibenz- b,f oxepine
AR008371A1 (es) * 1996-05-30 2000-01-19 Novartis Ag Una sal de adicion con acido de una 10-aminoalifatil-dibenz[b,f],oxepina, su empleo; procedimiento para su elaboracion, una 10-aminoalifatil-dibenz[b,f]oxepina, una preparacion farmaceutica que contiene dicha sal o dicha oxepina y un procedimiento para el tratamiento de enfermedades neurodegenerativ
US7078379B2 (en) 2002-06-03 2006-07-18 Santhera Pharmaceuticals (Schweiz) Gmbh Treatment of congenital muscular dystrophies
TW200505435A (en) 2003-01-29 2005-02-16 Novartis Ag Treatment of ocular disorders
AR046320A1 (es) 2003-11-06 2005-11-30 Novartis Ag Composiciones farmaceuticas estabilizadas de dibenzo-oxepina.
EP1757284A1 (de) * 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Verwendung von N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (Omigapil) zur Vorbeugung oder Behandlung der Muskulardystrophy

Also Published As

Publication number Publication date
US7875648B2 (en) 2011-01-25
AU2007236161B2 (en) 2009-12-10
JP4972156B2 (ja) 2012-07-11
ZA200807800B (en) 2009-06-24
WO2007115776A1 (en) 2007-10-18
CA2648155A1 (en) 2007-10-18
EP1842539A1 (de) 2007-10-10
PT2004176E (pt) 2011-11-23
ES2371627T3 (es) 2012-01-05
CY1112132T1 (el) 2015-11-04
MX2008012867A (es) 2008-10-13
CA2648155C (en) 2011-11-15
PL2004176T3 (pl) 2012-03-30
DK2004176T3 (da) 2012-02-06
NZ571129A (en) 2011-01-28
EP2004176A1 (de) 2008-12-24
AU2007236161A1 (en) 2007-10-18
SI2004176T1 (sl) 2012-01-31
JP2009532404A (ja) 2009-09-10
EP2004176B1 (de) 2011-10-26
US20090176867A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
EA201000050A1 (ru) Замещенные бициклолактамные соединения
IN2012DN01233A (de)
NZ596579A (en) Bace inhibitors
BR112012026948A2 (pt) composto, composição farmacêutica, e, métodos para melhorar o metabolismo ósseo, para previnir ou tratar uma doença associada com metabolismo ósseo e para previnir ou tratar osteoporose.
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2012007877A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
EA201170922A1 (ru) Производные сульфонамида
EA201270505A1 (ru) Производные иминотиадиазиндиоксида в качестве ингибиторов bace, композиции на их основе, и их применение
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
NO20076197L (no) Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
CY1112284T1 (el) Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων
NO20084328L (no) Nye forbindelser
EA201100872A1 (ru) Производные хиназолинамида
RU2492163C9 (ru) Соединения коричной кислоты (варианты), промежуточные соединения для их получения, фармацевтическая композиция на их основе, способ ингибирования гистоновой деацетилазы, способ лечения диабета, способ лечения опухоли или заболевания, связанного с пролиферацией клеток, способ усиления роста аксонов и способ лечения нейродегенеративных заболеваний и спинной мышечной атрофии
MX2011011080A (es) Antagonistas de ccr3 de arilsulfonamida 2, 5-disustituida.
WO2007111983A8 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
ATE530181T1 (de) Verwendung von n- ( dibenz (b, f) oxepin-10- ylmethyl ) n-methyl-n- prop- 2 -ynylamin (omigapil) zur prophylaxe und/oder behandlung von angeborener muskeldystrophie oder myopathie durch kollagenmangel
TW200800993A (en) Organic compounds
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200637817A (en) 5-aminoindole derivatives
ATE466007T1 (de) 5-substituierte indol-2-carbonsäureamidderivate
ATE429910T1 (de) Chlor enthaltende guanabenz derivate zur behandlung von prionerkrankungen
MXPA05008331A (es) Derivados de 3-(benzoilureido)-tiofeno sustituido, metodo para su produccion y uso de los mismos.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2004176

Country of ref document: EP